Risperidone extended release - Xbrane
Alternative Names: RisperisphereLatest Information Update: 24 Aug 2023
At a glance
- Originator Primm srl
- Developer Xbrane
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Aggression; Autistic disorder; Bipolar depression; Dementia; Schizophrenia
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Aggression in Sweden (IV-injection)
- 24 Aug 2023 Discontinued - Preclinical for Autistic disorder in Sweden (IV-injection)
- 24 Aug 2023 Discontinued - Preclinical for Bipolar depression in Sweden (IV-injection)